Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
β-LapachoneCat. No. 1293 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 3,4-Dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione |
Biological Activity
DNA topoisomerase I inhibitor. Exhibits a different inhibitory mechanism to camptothecin (Cat. No. 1100). Induces apoptosis in a variety of cell lines, including prostate cancer and promyelocytic leukemia cells; blocks the cell cycle in G0/G1. Also has effects on DNA topoisomerase II, NF-κB, AP-1, and JNK.Certificate of Analysis / Safety Data Sheet
References
Li et al (1993) Beta-Lapachone, a novel topoisomerase I inhibitor with a mode of action different from camptothecin. J.Biol.Chem. 268 22463. PMID: 8226754.
Wuerzberger et al (1998) Induction of apoptosis in MCF-7:WS8 breast cancer cells by β-Lapachone. Cancer Res. 58 1876. PMID: 9581828.
Manna et al (1999) Suppression of tumor necrosis factor-activated nuclear transcription factor-κB, activator protein-1, c-Jun N-terminal kinase, and apoptosis by β lapachone. Biochem.Pharmacol. 57 763. PMID: 10075082.
Shiah et al (1999) Activation of c-Jun NH2-terminal kinase and subsequent CPP32/Yama during topoisomerase inhibitor β-lapachone-induced apoptosis through an oxidation-dependent pathway Cancer Res. 59 391. PMID: 9927052.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: b-Lapachone, supplier, DNA, topoisomerase, I, inhibitors, apoptosis, proapoptotic, b-lapachone, beta-lapachone, β-lapachone
Quick Order
Find multiple products by catalog number
Cancer Research Guide
Request your free copy
Highlights over 350 products for cancer research. Request a copy or view PDF today.
Checkpoint Kinases & the DNA Damage Response
Written by Michelle D. Garrett and Ian Collins
A summary of the response of the checkpoint kinase signaling network to DNA damage, including activation of DNA repair, cell-cycle arrest, senescence and apoptosis.
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.